New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
New York and California Prepare For Potential Mifepristone Ban In Texas With Stockpiling Of Alternative Abortion Medications
紐約和加利福尼亞州通過儲存替代墮胎藥物，爲德克薩斯州可能的米非司酮禁令做準備
- New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this week.
- The alternative option, misoprostol, is FDA-approved to treat gastric ulcers, noted CNBC. But the use of misoprostol alone to induce abortions is endorsed by the World Health Organization and is used in countries where mifepristone is unavailable.
- Also Read: Attorney Generals of Over 20 States Sound Alarm Over Suspension Of Abortion Med Approval: "Devastating Risks" Ahead.
- It will remain on the market if U.S. District Judge Matthew Kacsmaryk's order suspending mifepristone takes effect this week Saturday.
- More than half of abortions in the U.S. use a combination of mifepristone and misoprostol.
- Some U.S. abortion providers are prepared to offer misoprostol as a stand-alone treatment, CNBC reported citing Jenny Ma, senior staff attorney at the Center for Reproductive Rights, a legal advocacy group representing abortion providers worldwide. Ma also said that other providers might not be ready to switch to a misoprostol-only regimen.
- New York Gov. Kathy Hochul ordered the state health department to purchase 150,000 doses of misoprostol, a five-year pill supply. Hochul's announcement comes a day after Gov. Gavin Newsom said California has secured 2 million misoprostol pills.
- Hochul said she is working with New York's legislature to require private insurers to cover misoprostol when prescribed off-label for abortions.
- The Justice Department and Danco Laboratories, the distributor of mifepristone, have asked the U.S. 5th Circuit Court of Appeals to block Kacsmaryk's ruling by noon Thursday.
- Photo via Wikimedia Commons
- 紐約州和加利福尼亞州正在儲備替代墮胎藥物，以防得克薩斯州法官暫停美國食品藥品管理局對主要藥物米非司酮的批准的命令在本週晚些時候生效。
- CNBC指出，替代方案米索前列醇已獲美國食品藥品管理局批准用於治療胃潰瘍。但是，僅使用米索前列醇誘導墮胎得到了世界衛生組織的認可，並且在無法獲得米非司酮的國家中使用。
- 另請閱讀： 20多個州的總檢察長對暫停墮胎藥物批准敲響警鐘：未來有 “毀滅性風險”。
- 如果美國地方法院法官馬修·卡斯馬雷克暫停米非司酮的命令在本週六生效，它將繼續在市場上銷售。
- 在美國，超過一半的墮胎同時使用米非司酮和米索前列醇。
- CNBC援引代表全球墮胎提供者的法律倡導組織生殖權利中心高級律師珍妮·馬的話報道，一些美國墮胎提供者準備將米索前列醇作爲獨立治療方法提供。馬雲還表示，其他提供者可能還沒有準備好改用僅限米索前列醇的治療方案。
- 紐約州州長凱西·霍赫爾命令州衛生部門購買15萬劑米索前列醇，這是爲期五年的藥丸供應。Hochul宣佈這一消息的前一天，州長加文·紐瑟姆表示加利福尼亞州已獲得200萬粒米索前列醇藥丸。
- 霍赫爾說，她正在與紐約州立法機關合作，要求私人保險公司爲標籤外的墮胎處方提供米索前列醇的保險。
- 司法部和米非司酮的分銷商丹科實驗室已要求美國第五巡迴上訴法院在週四中午之前阻止Kacsmaryk的裁決。
- 照片來自維基共享資源